Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids

Journal of Nutritional Biochemistry

Volumn 26, Issue 6, 2015, Pages 571-584

  Bhaswant, Maharshi ^a,c   Poudyal, Hemant ^b   Brown, Lindsay ^c  

^a VICTORIA UNIVERSITY   (Australia)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Adipokines; Inflammation; Insulin; N 3 polyunsaturated fatty acids; Obesity

Indexed keywords

ADIPOCYTOKINE; APELIN; DOCOSAHEXAENOIC ACID; GLUCAGON LIKE PEPTIDE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; ICOSAPENTAENOIC ACID; INSULIN; LINOLENIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SOMATOMEDIN C; UNSATURATED FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

DOWN REGULATION; ENTEROENDOCRINE CELL; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; OBESITY; PANCREAS ISLET BETA CELL; REVIEW; UPREGULATION; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; SECRETION (PROCESS);

ANIMALIA;

ADIPOKINES; ALPHA-LINOLENIC ACID; ANIMALS; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DOWN-REGULATION; EICOSAPENTAENOIC ACID; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; PPAR ALPHA; UP-REGULATION;

EID: 84928926236     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.02.001     Document Type: Review

References (232)

1. American Diabetes A Diagnosis and classification of diabetes mellitus. Diabetes Care 2011, 34(Suppl 1):S62-S69.
2. International Diabetes Federation IDF diabetes atlas 2013, International Diabetes Federation, Brussels, Belgium, [http://www.idf.org/sites/default/files/Atlas-poster-2014EN.pdf]. 6th ed.
3. Weir G.C., Laybutt D.R., Kaneto H., Bonner-Weir S., Sharma A. β-cell adaptation and decompensation during the progression of diabetes. Diabetes 2001, 50(Suppl 1):S154-S159.
4. Cnop M., Welsh N., Jonas J.C., Jorns A., Lenzen S., Eizirik D.L. Mechanisms of pancreatic β-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005, 54(Suppl 2):S97-S107.
5. Krssak M., Falk Petersen K., Dresner A., DiPietro L., Vogel S.M., Rothman D.L., et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999, 42:113-116.
6. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
7. Le K.A., Ith M., Kreis R., Faeh D., Bortolotti M., Tran C., et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009, 89:1760-1765.
8. Ravussin E., Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance, and type 2 diabetes mellitus. Ann N Y Acad Sci 2002, 967:363-378.
9. Chen G., Liang G., Ou J., Goldstein J.L., Brown M.S. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004, 101:11245-11250.
10. Ferre P., Foufelle F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab 2010, 12(Suppl 2):83-92.
11. Haluzik M.M., Haluzik M. PPAR-alpha and insulin sensitivity. Physiol Res 2006, 55:115-122.
12. Kintscher U., Law R.E. PPARγ-mediated insulin sensitization: the importance of fat versus muscle. Am J Physiol Endocrinol Metab 2005, 288:E287-E291.
13. Holst J.J. The physiology of glucagon-like peptide 1. Physiol Rev 2007, 87:1409-1439.
14. Clemmons D.R. Metabolic actions of IGF-1 in normal physiology and diabetes. Endocrinol Metab Clin North Am 2012, 41:425-443.
15. Xu S., Tsao P.S., Yue P. Apelin and insulin resistance: another arrow for the quiver?. J Diabetes 2011, 3:225-231.
16. Castan-Laurell I., Dray C., Knauf C., Kunduzova O., Valet P. Apelin, a promising target for type 2 diabetes treatment?. Trends Endocrinol Metab 2012, 23:234-241.
17. Kwon H., Pessin J.E. Adipokines mediate inflammation and insulin resistance. Front Endocrinol (Lausanne) 2013, 4:71.
18. Antuna-Puente B., Feve B., Fellahi S., Bastard J.P. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34:2-11.
19. Riserus U., Willett W.C., Hu F.B. Dietary fats and prevention of type 2 diabetes. Prog Lipid Res 2009, 48:44-51.
20. Galgani J.E., Uauy R.D., Aguirre C.A., Diaz E.O. Effect of the dietary fat quality on insulin sensitivity. Br J Nutr 2008, 100:471-479.
21. Martins A.R., Nachbar R.T., Gorjao R., Vinolo M.A., Festuccia W.T., Lambertucci R.H., et al. Mechanisms underlying skeletal muscle insulin resistance induced by fatty acids: importance of the mitochondrial function. Lipids Health Dis 2012, 11:30.
22. Thompson A.K., Minihane A.M., Williams C.M. Trans fatty acids, insulin resistance and diabetes. Eur J Clin Nutr 2011, 65:553-564.
23. Poudyal H., Panchal S.K., Diwan V., Brown L. Omega-3 fatty acids and metabolic syndrome: effects and emerging mechanisms of action. Prog Lipid Res 2011, 50:372-387.
24. Poudyal H., Panchal S.K., Ward L.C., Waanders J., Brown L. Chronic high-carbohydrate, high-fat feeding in rats induces reversible metabolic, cardiovascular, and liver changes. Am J Physiol Endocrinol Metab 2012, 302:E1472-E1482.
25. Poudyal H., Panchal S.K., Ward L.C., Brown L. Effects of ALA, EPA and DHA in high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. J Nutr Biochem 2013, 24:1041-1052.
26. Lorente-Cebrian S., Costa A.G., Navas-Carretero S., Zabala M., Martinez J.A., Moreno-Aliaga M.J. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem 2013, 69:633-651.
27. Juarez-Lopez C., Klunder-Klunder M., Madrigal-Azcarate A., Flores-Huerta S. Omega-3 polyunsaturated fatty acids reduce insulin resistance and triglycerides in obese children and adolescents. Pediatr Diabetes 2013, 14:377-383.
28. Jafari T., Fallah A.A., Azadbakht L. Role of dietary n-3 polyunsaturated fatty acids in type 2 diabetes: a review of epidemiological and clinical studies. Maturitas 2013, 74:303-308.
29. Fedor D., Kelley D.S. Prevention of insulin resistance by n-3 polyunsaturated fatty acids. Curr Opin Clin Nutr Metab Care 2009, 12:138-146.
30. Andersen G., Harnack K., Erbersdobler H.F., Somoza V. Dietary eicosapentaenoic acid and docosahexaenoic acid are more effective than alpha-linolenic acid in improving insulin sensitivity in rats. Ann Nutr Metab 2008, 52:250-256.
31. Agrawal R., Gomez-Pinilla F. 'Metabolic syndrome' in the brain: deficiency in omega-3 fatty acid exacerbates dysfunctions in insulin receptor signalling and cognition. J Physiol 2012, 590:2485-2499.
32. Gingras A.A., White P.J., Chouinard P.Y., Julien P., Davis T.A., Dombrowski L., et al. Long-chain omega-3 fatty acids regulate bovine whole-body protein metabolism by promoting muscle insulin signalling to the Akt-mTOR-S6K1 pathway and insulin sensitivity. J Physiol 2007, 579:269-284.
33. Kamolrat T., Gray S.R., Thivierge M.C. Fish oil positively regulates anabolic signalling alongside an increase in whole-body gluconeogenesis in ageing skeletal muscle. Eur J Nutr 2013, 52:647-657.
34. Cancelas J., Prieto P.G., Villanueva-Penacarrillo M.L., Zhang Y., Portois L., Sener A., et al. Glucose intolerance associated to insulin resistance and increased insulin secretion in rats depleted in long-chain ω3 fatty acids. Horm Metab Res 2007, 39:823-825.
35. Gonzalez-Periz A., Horrillo R., Ferre N., Gronert K., Dong B., Moran-Salvador E., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by ω-3 fatty acids: a role for resolvins and protectins. FASEB J 2009, 23:1946-1957.
36. Yang L., Yuan J., Liu L., Shi C., Wang L., Tian F., et al. α-Linolenic acid inhibits human renal cell carcinoma cell proliferation through PPAR-gamma activation and COX-2 inhibition. Oncol Lett 2013, 6:197-202.
37. Neschen S., Morino K., Dong J., Wang-Fischer Y., Cline G.W., Romanelli A.J., et al. n-3 Fatty acids preserve insulin sensitivity in vivo in a peroxisome proliferator-activated receptor-α-dependent manner. Diabetes 2007, 56:1034-1041.
38. Akinkuolie A.O., Ngwa J.S., Meigs J.B., Djousse L. Omega-3 polyunsaturated fatty acid and insulin sensitivity: a meta-analysis of randomized controlled trials. Clin Nutr 2011, 30:702-707.
39. Seino S., Shibasaki T., Minami K. Dynamics of insulin secretion and the clinical implications for obesity and diabetes. J Clin Invest 2011, 121:2118-2125.
40. Cavaghan M.K., Ehrmann D.A., Polonsky K.S. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000, 106:329-333.
41. Oguzhan B., Zhang Y., Louchami K., Courtois P., Portois L., Chardigny J.M., et al. Pancreatic islet function in ω3 fatty acid-depleted rats: glucose metabolism and nutrient-stimulated insulin release. Endocrine 2006, 29:457-466.
42. Zhang Y., Oguzhan B., Louchami K., Chardigny J.M., Portois L., Carpentier Y.A., et al. Pancreatic islet function in ω-3 fatty acid-depleted rats: alteration of calcium fluxes and calcium-dependent insulin release. Am J Physiol Endocrinol Metab 2006, 291:E441-E448.
43. + fluxes and insulin release in pancreatic islets from ω3 fatty acid-depleted rats. Endocrine 2006, 30:207-211.
44. + handling and secretory behaviour provoked by the intravenous administration of a medium-chain triglyceride: fish oil emulsion to long-chain polyunsaturated ω3 fatty acid-depleted rats. Int J Mol Med 2006, 18:1047-1055.
45. Pighin D., Karabatas L., Rossi A., Chicco A., Basabe J.C., Lombardo Y.B. Fish oil affects pancreatic fat storage, pyruvate dehydrogenase complex activity and insulin secretion in rats fed a sucrose-rich diet. J Nutr 2003, 133:4095-4101.
46. Holness M.J., Smith N.D., Greenwood G.K., Sugden M.C. Acute ω-3 fatty acid enrichment selectively reverses high-saturated fat feeding-induced insulin hypersecretion but does not improve peripheral insulin resistance. Diabetes 2004, 53(Suppl 1):S166-S171.
47. Robbez Masson V., Lucas A., Gueugneau A.M., Macaire J.P., Paul J.L., Grynberg A., et al. Long-chain (n-3) polyunsaturated fatty acids prevent metabolic and vascular disorders in fructose-fed rats. J Nutr 2008, 138:1915-1922.
48. Chicco A., D'Alessandro M.E., Karabatas L., Gutman R., Lombardo Y.B. Effect of moderate levels of dietary fish oil on insulin secretion and sensitivity, and pancreas insulin content in normal rats. Ann Nutr Metab 1996, 40:61-70.
49. Mellouk Z., Zhang Y., Bulur N., Louchami K., Malaisse W.J., Ait Yahia D., et al. The metabolic syndrome of fructose-fed rats: effects of long-chain polyunsaturated ω3 and ω6 fatty acids. III. Secretory behaviour of isolated pancreatic islets. Int J Mol Med 2012, 29:285-290.
50. Holness M.J., Greenwood G.K., Smith N.D., Sugden M.C. Diabetogenic impact of long-chain ω-3 fatty acids on pancreatic beta-cell function and the regulation of endogenous glucose production. Endocrinology 2003, 144:3958-3968.
51. Smith G.I., Atherton P., Reeds D.N., Mohammed B.S., Rankin D., Rennie M.J., et al. Omega-3 polyunsaturated fatty acids augment the muscle protein anabolic response to hyperinsulinaemia-hyperaminoacidaemia in healthy young and middle-aged men and women. Clin Sci (Lond) 2011, 121:267-278.
52. Yu X., Cui L., Zhang Z., Zhao Q., Li S. α-Linolenic acid attenuates doxorubicin-induced cardiotoxicity in rats through suppression of oxidative stress and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2013, 45:817-826.
53. Xie N., Zhang W., Li J., Liang H., Zhou H., Duan W., et al. α-Linolenic acid intake attenuates myocardial ischemia/reperfusion injury through anti-inflammatory and anti-oxidative stress effects in diabetic but not normal rats. Arch Med Res 2011, 42:171-181.
54. Zhang W., Li R., Li J., Wang W., Tie R., Tian F., et al. Alpha-linolenic acid exerts an endothelial protective effect against high glucose injury via PI3K/Akt pathway. PLoS One 2013, 8:e68489.
55. Zhang W., Wang R., Han S.F., Bu L., Wang S.W., Ma H., et al. α-linolenic acid attenuates high glucose-induced apoptosis in cultured human umbilical vein endothelial cells via PI3K/Akt/eNOS pathway. Nutrition 2007, 23:762-770.
56. Wei D., Li J., Shen M., Jia W., Chen N., Chen T., et al. Cellular production of n-3 PUFAs and reduction of n-6-to-n-3 ratios in the pancreatic β-cells and islets enhance insulin secretion and confer protection against cytokine-induced cell death. Diabetes 2010, 59:471-478.
57. Lopez S., Bermudez B., Ortega A., Varela L.M., Pacheco Y.M., Villar J., et al. Effects of meals rich in either monounsaturated or saturated fat on lipid concentrations and on insulin secretion and action in subjects with high fasting triglyceride concentrations. Am J Clin Nutr 2011, 93:494-499.
58. Xiao C., Giacca A., Carpentier A., Lewis G.F. Differential effects of monounsaturated, polyunsaturated and saturated fat ingestion on glucose-stimulated insulin secretion, sensitivity and clearance in overweight and obese, non-diabetic humans. Diabetologia 2006, 49:1371-1379.
59. Dobbins R.L., Chester M.W., Stevenson B.E., Daniels M.B., Stein D.T., McGarry J.D. A fatty acid- dependent step is critically important for both glucose- and non-glucose-stimulated insulin secretion. J Clin Invest 1998, 101:2370-2376.
60. Dobbins R.L., Chester M.W., Daniels M.B., McGarry J.D., Stein D.T. Circulating fatty acids are essential for efficient glucose-stimulated insulin secretion after prolonged fasting in humans. Diabetes 1998, 47:1613-1618.
61. Boden G., Chen X., Iqbal N. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects. Diabetes 1998, 47:1609-1612.
62. Pereira S., Breen D.M., Naassan A.E., Wang P.Y.T., Uchino H., Fantus I.G. In vivo effects of polyunsaturated, monounsaturated, and saturated fatty acids on hepatic and peripheral insulin sensitivity. Metabolism 2015, 64:315-322.
63. Wendland E., Farmer A., Glasziou P., Neil A. Effect of alpha linolenic acid on cardiovascular risk markers: a systematic review. Heart 2006, 92:166-169.
64. Djousse L., Hunt S.C., Tang W., Eckfeldt J.H., Province M.A., Ellison R.C. Dietary linolenic acid and fasting glucose and insulin: the National Heart, Lung, and Blood Institute Family Heart Study. Obesity (Silver Spring) 2006, 14:295-300.
65. Muramatsu T., Yatsuya H., Toyoshima H., Sasaki S., Li Y., Otsuka R., et al. Higher dietary intake of alpha-linolenic acid is associated with lower insulin resistance in middle-aged Japanese. Prev Med 2010, 50:272-276.
66. Kelley D.S., Vemuri M., Adkins Y., Gill S.H., Fedor D., Mackey B.E. Flaxseed oil prevents trans-10, cis-12-conjugated linoleic acid-induced insulin resistance in mice. Br J Nutr 2009, 101:701-708.
67. Ghafoorunissa, Ibrahim A., Natarajan S. Substituting dietary linoleic acid with alpha-linolenic acid improves insulin sensitivity in sucrose fed rats. Biochim Biophys Acta 2005, 1733:67-75.
68. Murase T., Aoki M., Tokimitsu I. Supplementation with α-linolenic acid-rich diacylglycerol suppresses fatty liver formation accompanied by an up-regulation of β-oxidation in Zucker fatty rats. Biochim Biophys Acta 2005, 1733:224-231.
69. Opara E.C., Hubbard V.S., Burch W.M., Akwari O.E. Characterization of the insulinotropic potency of polyunsaturated fatty acids. Endocrinology 1992, 130:657-662.
70. Adachi T., Tanaka T., Takemoto K., Koshimizu T.A., Hirasawa A., Tsujimoto G. Free fatty acids administered into the colon promote the secretion of glucagon-like peptide-1 and insulin. Biochem Biophys Res Commun 2006, 340:332-337.
71. Adachi T., Yanaka H., Kanai H., Nozaki M., Takahara Y., Tsuda M., et al. Administration of perilla oil coated with Calshell increases glucagon-like peptide secretion. Biol Pharm Bull 2008, 31:1021-1023.
72. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
73. Moriya R., Shirakura T., Ito J., Mashiko S., Seo T. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice. Am J Physiol Endocrinol Metab 2009, 297:E1358-E1365.
74. +-d-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion. Diabetes 2012, 61:187-196.
75. Kaji I., Karaki S., Kuwahara A. Short-chain fatty acid receptor and its contribution to glucagon-like peptide-1 release. Digestion 2014, 89:31-36.
76. Xiong Y., Swaminath G., Cao Q., Yang L., Guo Q., Salomonis H., et al. Activation of FFA1 mediates GLP-1 secretion in mice. Evidence for allosterism at FFA1. Mol Cell Endocrinol 2013, 369:119-129.
77. Hara T., Hirasawa A., Sun Q., Sadakane K., Itsubo C., Iga T., et al. Novel selective ligands for free fatty acid receptors GPR120 and GPR40. Naunyn Schmiedebergs Arch Pharmacol 2009, 380:247-255.
78. Skelin M., Rupnik M., Cencic A. Pancreatic beta cell lines and their applications in diabetes mellitus research. ALTEX 2010, 27:105-113.
79. Tuo Y., Feng D.D., Wang D.F., Sun J., Li S.B., Chen C. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors. Clin Exp Pharmacol Physiol 2012, 39:423-428.
80. Paulsen S.J., Larsen L.K., Hansen G., Chelur S., Larsen P.J., Vrang N. Expression of the fatty acid receptor GPR120 in the gut of diet-induced-obese rats and its role in GLP-1 secretion. PLoS One 2014, 9:e88227.
81. Fang X.L., Shu G., Zhang Z.Q., Wang S.B., Zhu X.T., Gao P., et al. Roles of alpha-linolenic acid on IGF-I secretion and GH/IGF system gene expression in porcine primary hepatocytes. Mol Biol Rep 2012, 39:10987-10996.
82. Clemmons D.R. The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 2004, 113:25-27.
83. Sarbolouki S., Javanbakht M.H., Derakhshanian H., Hosseinzadeh P., Zareei M., Hashemi S.B., et al. Eicosapentaenoic acid improves insulin sensitivity and blood sugar in overweight type 2 diabetes mellitus patients: a double-blind randomised clinical trial. Singapore Med J 2013, 54:387-390.
84. Liu X., Xue Y., Liu C., Lou Q., Wang J., Yanagita T., et al. Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis 2013, 12:109.
85. Mori Y., Murakawa Y., Yokoyama J., Tajima N., Ikeda Y., Nobukata H., et al. Effect of highly purified eicosapentaenoic acid ethyl ester on insulin resistance and hypertension in Dahl salt-sensitive rats. Metabolism 1999, 48:1089-1095.
86. Mori Y., Murakawa Y., Katoh S., Hata S., Yokoyama J., Tajima N., et al. Influence of highly purified eicosapentaenoic acid ethyl ester on insulin resistance in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous non-insulin-dependent diabetes mellitus. Metabolism 1997, 46:1458-1464.
87. Nobukata H., Ishikawa T., Obata M., Shibutani Y. Long-term administration of highly purified eicosapentaenoic acid ethyl ester prevents diabetes and abnormalities of blood coagulation in male WBN/Kob rats. Metabolism 2000, 49:912-919.
88. Poudyal H., Brown L. The role of n-3 polyunsaturated fatty acids in human heart failure. Endocr Metab Immune Disord Drug Targets 2013, 13:105-117.
89. Leguisamo N.M., Lehnen A.M., Machado U.F., Okamoto M.M., Markoski M.M., Pinto G.H., et al. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol 2012, 11:100.
90. Armoni M., Harel C., Karnieli E. Transcriptional regulation of the GLUT4 gene: from PPAR-gamma and FOXO1 to FFA and inflammation. Trends Endocrinol Metab 2007, 18:100-107.
91. Perez-Matute P., Perez-Echarri N., Martinez J.A., Marti A., Moreno-Aliaga M.J. Eicosapentaenoic acid actions on adiposity and insulin resistance in control and high-fat-fed rats: role of apoptosis, adiponectin and tumour necrosis factor-α. Br J Nutr 2007, 97:389-398.
92. Kubota H., Matsumoto H., Higashida M., Murakami H., Nakashima H., Oka Y., et al. Eicosapentaenoic acid modifies cytokine activity and inhibits cell proliferation in an oesophageal cancer cell line. Anticancer Res 2013, 33:4319-4324.
93. Castillero E., Lopez-Menduina M., Martin A.I., Villanua M.A., Lopez-Calderon A. Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1. J Endocrinol 2011, 210:361-368.
94. Poulsen L., Siersbaek M., Mandrup S. PPARs: fatty acid sensors controlling metabolism. Semin Cell Dev Biol 2012, 23:631-639.
95. Bensinger S.J., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
96. Olefsky J.M., Saltiel A.R. PPAR γ and the treatment of insulin resistance. Trends Endocrinol Metab 2000, 11:362-368.
97. Chambrier C., Bastard J.P., Rieusset J., Chevillotte E., Bonnefont-Rousselot D., Therond P., et al. Eicosapentaenoic acid induces mRNA expression of peroxisome proliferator-activated receptor γ. Obes Res 2002, 10:518-525.
98. Li H., Ruan X.Z., Powis S.H., Fernando R., Mon W.Y., Wheeler D.C., et al. EPA and DHA reduce LPS-induced inflammation responses in HK-2 cells: evidence for a PPAR-γ-dependent mechanism. Kidney Int 2005, 67:867-874.
99. Allred C.D., Talbert D.R., Southard R.C., Wang X., Kilgore M.W. PPARγ1 as a molecular target of eicosapentaenoic acid in human colon cancer (HT-29) cells. J Nutr 2008, 138:250-256.
100. Lorente-Cebrian S., Perez-Matute P., Martinez J.A., Marti A., Moreno-Aliaga M.J. Effects of eicosapentaenoic acid (EPA) on adiponectin gene expression and secretion in primary cultured rat adipocytes. J Physiol Biochem 2006, 62:61-69.
101. Bedoucha M., Atzpodien E., Boelsterli U.A. Diabetic KKAy mice exhibit increased hepatic PPARγ1 gene expression and develop hepatic steatosis upon chronic treatment with antidiabetic thiazolidinediones. J Hepatol 2001, 35:17-23.
102. Oribe J., Kakuma T., Haranaka M., Okamoto K., Seike M., Yoshimatsu H. Intraperitoneal administration attenuates thiazolidinedione-induced hepatic steatosis in KKAy mice with increased hepatic peroxisome proliferator-activated receptor (PPAR)γ mRNA expression. Obes Res Clin Pract 2012, 6:e175-e262.
103. Peng J., Huan Y., Jiang Q., Sun S.-J., Jia C.-M., Shen Z.-F. Effects and potential mechanisms of pioglitazone on lipid metabolism in obese diabetic KKAy mice. PPAR Res 2014, 2014:538183.
104. Kato T., Shimano H., Yamamoto T., Ishikawa M., Kumadaki S., Matsuzaka T., et al. Palmitate impairs and eicosapentaenoate restores insulin secretion through regulation of SREBP-1c in pancreatic islets. Diabetes 2008, 57:2382-2392.
105. Shao S., Liu Z., Yang Y., Zhang M., Yu X. SREBP-1c, Pdx-1, and GLP-1R involved in palmitate-EPA regulated glucose-stimulated insulin secretion in INS-1 cells. J Cell Biochem 2010, 111:634-642.
106. Bertrand C., Pignalosa A., Wanecq E., Rancoule C., Batut A., Deleruyelle S., et al. Effects of dietary eicosapentaenoic acid (EPA) supplementation in high-fat fed mice on lipid metabolism and apelin/APJ system in skeletal muscle. PLoS One 2013, 8:e78874.
107. Konard R.J., Stoller J.Z., Gao Z.Y., Wolf B.A. Eicosapentaenoic acid (C20:5) augments glucose-induced insulin secretion from β-TC3 insulinoma cells. Pancreas 1996, 13:253-258.
108. Guo L., Li Q., Wang W., Yu P., Pan H., Li P., et al. Apelin inhibits insulin secretion in pancreatic β-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res 2009, 34:142-154.
109. Dray C., Knauf C., Daviaud D., Waget A., Boucher J., Buleon M., et al. Apelin stimulates glucose utilization in normal and obese insulin-resistant mice. Cell Metab 2008, 8:437-445.
110. Morishita M., Tanaka T., Shida T., Takayama K. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release 2008, 132:99-104.
111. Kogure R., Toyama K., Hiyamuta S., Kojima I., Takeda S. 5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion. Biochem Biophys Res Commun 2011, 416:58-63.
112. Shimura T., Miura T., Usami M., Ishihara E., Tanigawa K., Ishida H., et al. Docosahexanoic acid (DHA) improved glucose and lipid metabolism in KK-Ay mice with genetic non-insulin-dependent diabetes mellitus (NIDDM). Biol Pharm Bull 1997, 20:507-510.
113. Vemuri M., Kelley D.S., Mackey B.E., Rasooly R., Bartolini G. Docosahexaenoic acid (DHA) but not eicosapentaenoic acid (EPA) prevents trans-10, cis-12 conjugated linoleic acid (CLA)-induced insulin resistance in mice. Metab Syndr Relat Disord 2007, 5:315-322.
114. Oliver E., McGillicuddy F.C., Harford K.A., Reynolds C.M., Phillips C.M., Ferguson J.F., et al. Docosahexaenoic acid attenuates macrophage-induced inflammation and improves insulin sensitivity in adipocytes-specific differential effects between LC n-3 PUFA. J Nutr Biochem 2012, 23:1192-1200.
115. Howell G., Deng X., Yellaturu C., Park E.A., Wilcox H.G., Raghow R., et al. N-3 polyunsaturated fatty acids suppress insulin-induced SREBP-1c transcription via reduced trans-activating capacity of LXRα. Biochim Biophys Acta 2009, 1791:1190-1196.
116. Poudyal H., Brown L. Stearoyl-CoA desaturase: a vital checkpoint in the development and progression of obesity. Endocr Metab Immune Disord Drug Targets 2011, 11:217-231.
117. Shida T., Kamei N., Takeda-Morishita M., Isowa K., Takayama K. Colonic delivery of docosahexaenoic acid improves impaired glucose tolerance via GLP-1 secretion and suppresses pancreatic islet hyperplasia in diabetic KK-A(y) mice. Int J Pharm 2013, 450:63-69.
118. Hirasawa A., Tsumaya K., Awaji T., Katsuma S., Adachi T., Yamada M., et al. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 2005, 11:90-94.
119. Aldhahi W., Hamdy O. Adipokines, inflammation, and the endothelium in diabetes. Curr Diab Rep 2003, 3:293-298.
120. Johnson R.J., Stenvinkel P., Martin S.L., Jani A., Sanchez-Lozada L.G., Hill J.O., et al. Redefining metabolic syndrome as a fat storage condition based on studies of comparative physiology. Obesity (Silver Spring) 2013, 21:659-664.
121. Di Lorenzo C., Dell'agli M., Colombo E., Sangiovanni E., Restani P. Metabolic syndrome and inflammation: a critical review of in vitro and clinical approaches for benefit assessment of plant food supplements. Evid Based Complement Alternat Med 2013, 2013:782461.
122. De Caterina R., Libby P. Control of endothelial leukocyte adhesion molecules by fatty acids. Lipids 1996, 31:S57-S63. [Suppl].
123. Khalfoun B., Thibault F., Watier H., Bardos P., Lebranchu Y. Docosahexaenoic and eicosapentaenoic acids inhibit in vitro human endothelial cell production of interleukin-6. Adv Exp Med Biol 1997, 400B:589-597.
124. Caughey G.E., Mantzioris E., Gibson R.A., Cleland L.G., James M.J. The effect on human tumor necrosis factor α and interleukin 1 β production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr 1996, 63:116-122.
125. Chavali S.R., Zhong W.W., Forse R.A. Dietary α-linolenic acid increases TNF-α, and decreases IL-6, IL-10 in response to LPS: effects of sesamin on the delta-5 desaturation of omega6 and omega3 fatty acids in mice. Prostaglandins Leukot Essent Fatty Acids 1998, 58:185-191.
126. Kalupahana N.S., Claycombe K.J., Moustaid-Moussa N. (n-3) Fatty acids alleviate adipose tissue inflammation and insulin resistance: mechanistic insights. Adv Nutr 2011, 2:304-316.
127. Shoelson S.E., Lee J., Goldfine A.B. Inflammation and insulin resistance. J Clin Invest 2006, 116:1793-1801.
128. Olefsky J.M., Glass C.K. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246.
129. Iyer A., Fairlie D.P., Prins J.B., Hammock B.D., Brown L. Inflammatory lipid mediators in adipocyte function and obesity. Nat Rev Endocrinol 2010, 6:71-82.
130. Tilg H., Moschen A.R. Role of adiponectin and PBEF/visfatin as regulators of inflammation: involvement in obesity-associated diseases. Clin Sci (Lond) 2008, 114:275-288.
131. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
132. O'Rourke R.W. Inflammation in obesity-related diseases. Surgery 2009, 145:255-259.
133. Ohashi K., Shibata R., Murohara T., Ouchi N. Role of anti-inflammatory adipokines in obesity-related diseases. Trends Endocrinol Metab 2014, 25:348-355.
134. Bluher M. Adipokines - removing road blocks to obesity and diabetes therapy. Mol Metab 2014, 3:230-240.
135. Segal K.R., Landt M., Klein S. Relationship between insulin sensitivity and plasma leptin concentration in lean and obese men. Diabetes 1996, 45:988-991.
136. Crujeiras A.B., Goyenechea E., Abete I., Lage M., Carreira M.C., Martinez J.A., et al. Weight regain after a diet-induced loss is predicted by higher baseline leptin and lower ghrelin plasma levels. J Clin Endocrinol Metab 2010, 95:5037-5044.
137. Sivitz W.I., Walsh S.A., Morgan D.A., Thomas M.J., Haynes W.G. Effects of leptin on insulin sensitivity in normal rats. Endocrinology 1997, 138:3395-3401.
138. Shek E.W., Brands M.W., Hall J.E. Chronic leptin infusion increases arterial pressure. Hypertension 1998, 31:409-414.
139. Denroche H.C., Huynh F.K., Kieffer T.J. The role of leptin in glucose homeostasis. J Diabetes Investig 2012, 3:115-129.
140. Minokoshi Y., Alquier T., Furukawa N., Kim Y.B., Lee A., Xue B., et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 2004, 428:569-574.
141. Morton G.J. Hypothalamic leptin regulation of energy homeostasis and glucose metabolism. J Physiol 2007, 583:437-443.
142. Ceddia R.B., William W.N., Curi R. Comparing effects of leptin and insulin on glucose metabolism in skeletal muscle: evidence for an effect of leptin on glucose uptake and decarboxylation. Int J Obes Relat Metab Disord 1999, 23:75-82.
143. Minokoshi Y., Haque M.S., Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 1999, 48:287-291.
144. Emilsson V., Liu Y.L., Cawthorne M.A., Morton N.M., Davenport M. Expression of the functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 1997, 46:313-316.
145. Della-Fera M.A., Choi Y.H., Hartzell D.L., Duan J., Hamrick M., Baile C.A. Sensitivity of ob/ob mice to leptin-induced adipose tissue apoptosis. Obes Res 2005, 13:1540-1547.
146. Ueno N., Inui A., Kalra P.S., Kalra S.P. Leptin transgene expression in the hypothalamus enforces euglycemia in diabetic, insulin-deficient nonobese Akita mice and leptin-deficient obese ob/ob mice. Peptides 2006, 27:2332-2342.
147. Hidaka S., Yoshimatsu H., Kondou S., Tsuruta Y., Oka K., Noguchi H., et al. Chronic central leptin infusion restores hyperglycemia independent of food intake and insulin level in streptozotocin-induced diabetic rats. FASEB J 2002, 16:509-518.
148. Yaspelkis B.B., Singh M.K., Krisan A.D., Collins D.E., Kwong C.C., Bernard J.R., et al. Chronic leptin treatment enhances insulin-stimulated glucose disposal in skeletal muscle of high-fat fed rodents. Life Sci 2004, 74:1801-1816.
149. Berti L., Kellerer M., Capp E., Haring H.U. Leptin stimulates glucose transport and glycogen synthesis in C2C12 myotubes: evidence for a P13-kinase mediated effect. Diabetologia 1997, 40:606-609.
150. Sainz N., Rodriguez A., Catalan V., Becerril S., Ramirez B., Lancha A., et al. Leptin reduces the expression and increases the phosphorylation of the negative regulators of GLUT4 traffic TBC1D1 and TBC1D4 in muscle of ob/ob mice. PLoS One 2012, 7:e29389.
151. Benomar Y., Naour N., Aubourg A., Bailleux V., Gertler A., Djiane J., et al. Insulin and leptin induce Glut4 plasma membrane translocation and glucose uptake in a human neuronal cell line by a phosphatidylinositol 3-kinase-dependent mechanism. Endocrinology 2006, 147:2550-2556.
152. Gueugnon C., Mougin F., Simon-Rigaud M.L., Regnard J., Negre V., Dumoulin G. Effects of an in-patient treatment program based on regular exercise and a balanced diet on high molecular weight adiponectin, resistin levels, and insulin resistance in adolescents with severe obesity. Appl Physiol Nutr Metab 2012, 37:672-679.
153. Hotta K., Funahashi T., Arita Y., Takahashi M., Matsuda M., Okamoto Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000, 20:1595-1599.
154. Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006, 116:1784-1792.
155. Ouchi N., Kihara S., Arita Y., Maeda K., Kuriyama H., Okamoto Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation 1999, 100:2473-2476.
156. Menzaghi C., Trischitta V., Doria A. Genetic influences of adiponectin on insulin resistance, type 2 diabetes, and cardiovascular disease. Diabetes 2007, 56:1198-1209.
157. Yamauchi T., Kamon J., Minokoshi Y., Ito Y., Waki H., Uchida S., et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002, 8:1288-1295.
158. Tomas E., Tsao T.S., Saha A.K., Murrey H.E., Zhang Cc C., Itani S.I., et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A 2002, 99:16309-16313.
159. Berg A.H., Combs T.P., Du X., Brownlee M., Scherer P.E. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med 2001, 7:947-953.
160. Combs T.P., Berg A.H., Obici S., Scherer P.E., Rossetti L. Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 2001, 108:1875-1881.
161. Yamauchi T., Kamon J., Waki H., Imai Y., Shimozawa N., Hioki K., et al. Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 2003, 278:2461-2468.
162. Barnes K.M., Miner J.L. Role of resistin in insulin sensitivity in rodents and humans. Curr Protein Pept Sci 2009, 10:96-107.
163. Graveleau C., Zaha V.G., Mohajer A., Banerjee R.R., Dudley-Rucker N., Steppan C.M., et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 2005, 280:31679-31685.
164. Gharibeh M.Y., Al Tawallbeh G.M., Abboud M.M., Radaideh A., Alhader A.A., Khabour O.F. Correlation of plasma resistin with obesity and insulin resistance in type 2 diabetic patients. Diabetes Metab 2010, 36:443-449.
165. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., Watson W., Kerr K., Jones R., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 2003, 88:5452-5455.
166. Valsamakis G., McTernan P.G., Chetty R., Al Daghri N., Field A., Hanif W., et al. Modest weight loss and reduction in waist circumference after medical treatment are associated with favorable changes in serum adipocytokines. Metabolism 2004, 53:430-434.
167. Norata G.D., Ongari M., Garlaschelli K., Raselli S., Grigore L., Catapano A.L. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 2007, 156:279-284.
168. Wang H., Chen D.Y., Cao J., He Z.Y., Zhu B.P., Long M. High serum resistin level may be an indicator of the severity of coronary disease in acute coronary syndrome. Chin Med Sci J 2009, 24:161-166.
169. Rajala M.W., Obici S., Scherer P.E., Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production. J Clin Invest 2003, 111:225-230.
170. Banerjee R.R., Rangwala S.M., Shapiro J.S., Rich A.S., Rhoades B., Qi Y., et al. Regulation of fasted blood glucose by resistin. Science 2004, 303:1195-1198.
171. Steppan C.M., Wang J., Whiteman E.L., Birnbaum M.J., Lazar M.A. Activation of SOCS-3 by resistin. Mol Cell Biol 2005, 25:1569-1575.
172. Luo Z., Zhang Y., Li F., He J., Ding H., Yan L., et al. Resistin induces insulin resistance by both AMPK-dependent and AMPK-independent mechanisms in HepG2 cells. Endocrine 2009, 36:60-69.
173. Revollo J.R., Korner A., Mills K.F., Satoh A., Wang T., Garten A., et al. Nampt/PBEF/Visfatin regulates insulin secretion in β cells as a systemic NAD biosynthetic enzyme. Cell Metab 2007, 6:363-375.
174. Berndt J., Kloting N., Kralisch S., Kovacs P., Fasshauer M., Schon M.R., et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes 2005, 54:2911-2916.
175. Haider D.G., Schindler K., Schaller G., Prager G., Wolzt M., Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab 2006, 91:1578-1581.
176. Lopez-Bermejo A., Chico-Julia B., Fernandez-Balsells M., Recasens M., Esteve E., Casamitjana R., et al. Serum visfatin increases with progressive β-cell deterioration. Diabetes 2006, 55:2871-2875.
177. Aller R., de Luis D.A., Izaola O., Sagrado M.G., Conde R., Velasco M.C., et al. Influence of visfatin on histopathological changes of non-alcoholic fatty liver disease. Dig Dis Sci 2009, 54:1772-1777.
178. Takebayashi K., Suetsugu M., Wakabayashi S., Aso Y., Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism 2007, 56:451-458.
179. Chen M.P., Chung F.M., Chang D.M., Tsai J.C., Huang H.F., Shin S.J., et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006, 91:295-299.
180. Dogru T., Sonmez A., Tasci I., Bozoglu E., Yilmaz M.I., Genc H., et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007, 76:24-29.
181. Stofkova A. Resistin and visfatin: regulators of insulin sensitivity, inflammation and immunity. Endocr Regul 2010, 44:25-36.
182. Haider D.G., Holzer G., Schaller G., Weghuber D., Widhalm K., Wagner O., et al. The adipokine visfatin is markedly elevated in obese children. J Pediatr Gastroenterol Nutr 2006, 43:548-549.
183. Zahorska-Markiewicz B., Olszanecka-Glinianowicz M., Janowska J., Kocelak P., Semik-Grabarczyk E., Holecki M., et al. Serum concentration of visfatin in obese women. Metabolism 2007, 56:1131-1134.
184. Jin H., Jiang B., Tang J., Lu W., Wang W., Zhou L., et al. Serum visfatin concentrations in obese adolescents and its correlation with age and high-density lipoprotein cholesterol. Diabetes Res Clin Pract 2008, 79:412-418.
185. Sun C., Zhang F., Ge X., Yan T., Chen X., Shi X., et al. SIRT1 improves insulin sensitivity under insulin-resistant conditions by repressing PTP1B. Cell Metab 2007, 6:307-319.
186. Romacho T., Azcutia V., Vazquez-Bella M., Matesanz N., Cercas E., Nevado J., et al. Extracellular PBEF/NAMPT/visfatin activates pro-inflammatory signalling in human vascular smooth muscle cells through nicotinamide phosphoribosyltransferase activity. Diabetologia 2009, 52:2455-2463.
187. Liu S.W., Qiao S.B., Yuan J.S., Liu D.Q. Association of plasma visfatin levels with inflammation, atherosclerosis and acute coronary syndromes (ACS) in humans. Clin Endocrinol (Oxf) 2009, 71:202-207.
188. Zhong M., Tan H.W., Gong H.P., Wang S.F., Zhang Y., Zhang W. Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf) 2008, 69:878-884.
189. Lu L.F., Yang S.S., Wang C.P., Hung W.C., Yu T.H., Chiu C.A., et al. Elevated visfatin/pre-B-cell colony-enhancing factor plasma concentration in ischemic stroke. J Stroke Cerebrovasc Dis 2009, 18:354-359.
190. Choi Y.J., Choi S.E., Ha E.S., Kang Y., Han S.J., Kim D.J., et al. Extracellular visfatin activates gluconeogenesis in HepG2 cells through the classical PKA/CREB-dependent pathway. Horm Metab Res 2014, 46:233-239.
191. Saddi-Rosa P., Oliveira C.S., Giuffrida F.M., Reis A.F. Visfatin, glucose metabolism and vascular disease: a review of evidence. Diabetol Metab Syndr 2010, 2:21.
192. Poudyal H., Panchal S.K., Waanders J., Ward L., Brown L. Lipid redistribution by α-linolenic acid-rich chia seed inhibits stearoyl-CoA desaturase-1 and induces cardiac and hepatic protection in diet-induced obese rats. J Nutr Biochem 2012, 23:153-162.
193. Rhee Y., Brunt A. Flaxseed supplementation improved insulin resistance in obese glucose intolerant people: a randomized crossover design. Nutr J 2011, 10:44.
194. Carbonelli M.G., Di Renzo L., Bigioni M., Di Daniele N., De Lorenzo A., Fusco M.A. α-lipoic acid supplementation: a tool for obesity therapy?. Curr Pharm Des 2010, 16:840-846.
195. Kratz M., von Eckardstein A., Fobker M., Buyken A., Posny N., Schulte H., et al. The impact of dietary fat composition on serum leptin concentrations in healthy nonobese men and women. J Clin Endocrinol Metab 2002, 87:5008-5014.
196. Nelson T.L., Stevens J.R., Hickey M.S. Adiponectin levels are reduced, independent of polymorphisms in the adiponectin gene, after supplementation with α-linolenic acid among healthy adults. Metabolism 2007, 56:1209-1215.
197. Lozano A., Perez-Martinez P., Marin C., Tinahones F.J., Delgado-Lista J., Cruz-Teno C., et al. An acute intake of a walnut-enriched meal improves postprandial adiponectin response in healthy young adults. Nutr Res 2013, 33:1012-1018.
198. Sener A., Zhang Y., Bulur N., Louchami K., Malaisse W.J., Carpentier Y.A. The metabolic syndrome of ω3-depleted rats. II. Body weight, adipose tissue mass and glycemic homeostasis. Int J Mol Med 2009, 24:125-129.
199. Sekine S., Sasanuki S., Murano Y., Aoyama T., Takeuchi H. Alpha-linolenic acid-rich flaxseed oil ingestion increases plasma adiponectin level in rats. Int J Vitam Nutr Res 2008, 78:223-229.
200. Al-Suhaimi E.A., Shehzad A. Leptin, resistin and visfatin: the missing link between endocrine metabolic disorders and immunity. Eur J Med Res 2013, 18:12.
201. McCullough R.S., Edel A.L., Bassett C.M., Lavallee R.K., Dibrov E., Blackwood D.P., et al. The alpha linolenic acid content of flaxseed is associated with an induction of adipose leptin expression. Lipids 2011, 46:1043-1052.
202. Fukumitsu S., Villareal M.O., Onaga S., Aida K., Han J., Isoda H. alpha-Linolenic acid suppresses cholesterol and triacylglycerol biosynthesis pathway by suppressing SREBP-2, SREBP-1a and -1c expression. Cytotechnology 2013, 65:899-907.
203. Muhlhausler B.S., Cook-Johnson R., James M., Miljkovic D., Duthoit E., Gibson R. Opposing effects of omega-3 and omega-6 long chain polyunsaturated fatty acids on the expression of lipogenic genes in omental and retroperitoneal adipose depots in the rat. J Nutr Metab 2010, 2010:927836.
204. Rahmouni K., Sigmund C.D. Id3, E47, and SREBP-1c: fat factors controlling adiponectin expression. Circ Res 2008, 103:565-567.
205. Mason M.M., He Y., Chen H., Quon M.J., Reitman M. Regulation of leptin promoter function by Sp1, C/EBP, and a novel factor. Endocrinology 1998, 139:1013-1022.
206. Oliva M.E., Ferreira M.R., Chicco A., Lombardo Y.B. Dietary Salba (Salvia hispanica L) seed rich in α-linolenic acid improves adipose tissue dysfunction and the altered skeletal muscle glucose and lipid metabolism in dyslipidemic insulin-resistant rats. Prostaglandins Leukot Essent Fatty Acids 2013, 89:279-289.
207. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 2001, 7:941-946.
208. Fasshauer M., Klein J., Kralisch S., Klier M., Lossner U., Bluher M., et al. Growth hormone is a positive regulator of adiponectin receptor 2 in 3T3-L1 adipocytes. FEBS Lett 2004, 558:27-32.
209. Yoon M.J., Lee G.Y., Chung J.J., Ahn Y.H., Hong S.H., Kim J.B. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor α. Diabetes 2006, 55:2562-2570.
210. Zhao G., Etherton T.D., Martin K.R., West S.G., Gillies P.J., Kris-Etherton P.M. Dietary α-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 2004, 134:2991-2997.
211. Satoh N., Shimatsu A., Kotani K., Himeno A., Majima T., Yamada K., et al. Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome. Hypertens Res 2009, 32:1004-1008.
212. Itoh M., Suganami T., Satoh N., Tanimoto-Koyama K., Yuan X., Tanaka M., et al. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol 2007, 27:1918-1925.
213. Reseland J.E., Haugen F., Hollung K., Solvoll K., Halvorsen B., Brude I.R., et al. Reduction of leptin gene expression by dietary polyunsaturated fatty acids. J Lipid Res 2001, 42:743-750.
214. Kalupahana N.S., Claycombe K., Newman S.J., Stewart T., Siriwardhana N., Matthan N., et al. Eicosapentaenoic acid prevents and reverses insulin resistance in high-fat diet-induced obese mice via modulation of adipose tissue inflammation. J Nutr 2010, 140:1915-1922.
215. Figueras M., Olivan M., Busquets S., Lopez-Soriano F.J., Argiles J.M. Effects of eicosapentaenoic acid (EPA) treatment on insulin sensitivity in an animal model of diabetes: improvement of the inflammatory status. Obesity (Silver Spring) 2011, 19:362-369.
216. Sato A., Kawano H., Notsu T., Ohta M., Nakakuki M., Mizuguchi K., et al. Antiobesity effect of eicosapentaenoic acid in high-fat/high-sucrose diet-induced obesity: importance of hepatic lipogenesis. Diabetes 2010, 59:2495-2504.
217. Perez-Matute P., Marti A., Martinez J.A., Fernandez-Otero M.P., Stanhope K.L., Havel P.J., et al. Eicosapentaenoic fatty acid increases leptin secretion from primary cultured rat adipocytes: role of glucose metabolism. Am J Physiol Regul Integr Comp Physiol 2005, 288:R1682-R1688.
218. Kakuma T., Lee Y., Higa M., Wang Z., Pan W., Shimomura I., et al. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Acad Sci U S A 2000, 97:8536-8541.
219. Hulver M.W., Berggren J.R., Carper M.J., Miyazaki M., Ntambi J.M., Hoffman E.P., et al. Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab 2005, 2:251-261.
220. Kraegen E.W., Cooney G.J. Free fatty acids and skeletal muscle insulin resistance. Curr Opin Lipidol 2008, 19:235-241.
221. Biddinger S.B., Miyazaki M., Boucher J., Ntambi J.M., Kahn C.R. Leptin suppresses stearoyl-CoA desaturase 1 by mechanisms independent of insulin and sterol regulatory element-binding protein-1c. Diabetes 2006, 55:2032-2041.
222. Perez-Echarri N., Perez-Matute P., Marcos-Gomez B., Marti A., Martinez J.A., Moreno-Aliaga M.J. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats. J Nutr Biochem 2009, 20:705-714.
223. Banga A., Unal R., Tripathi P., Pokrovskaya I., Owens R.J., Kern P.A., et al. Adiponectin translation is increased by the PPARγ agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 2009, 296:E480-E489.
224. Tishinsky J.M., Ma D.W., Robinson L.E. Eicosapentaenoic acid and rosiglitazone increase adiponectin in an additive and PPARγ-dependent manner in human adipocytes. Obesity (Silver Spring) 2011, 19:262-268.
225. Salt I.P., Connell J.M., Gould G.W. 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) inhibits insulin-stimulated glucose transport in 3T3-L1 adipocytes. Diabetes 2000, 49:1649-1656.
226. Haugen F., Zahid N., Dalen K.T., Hollung K., Nebb H.I., Drevon C.A. Resistin expression in 3T3-L1 adipocytes is reduced by arachidonic acid. J Lipid Res 2005, 46:143-153.
227. Perez-Echarri N., Perez-Matute P., Marcos-Gomez B., Martinez J.A., Moreno-Aliaga M.J. Effects of eicosapentaenoic acid ethyl ester on visfatin and apelin in lean and overweight (cafeteria diet-fed) rats. Br J Nutr 2009, 101:1059-1067.
228. Moschen A.R., Kaser A., Enrich B., Mosheimer B., Theurl M., Niederegger H., et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007, 178:1748-1758.
229. Raclot T., Groscolas R., Langin D., Ferre P. Site-specific regulation of gene expression by n-3 polyunsaturated fatty acids in rat white adipose tissues. J Lipid Res 1997, 38:1963-1972.
230. Flachs P., Horakova O., Brauner P., Rossmeisl M., Pecina P., Franssen-van Hal N., et al. Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce β-oxidation in white fat. Diabetologia 2005, 48:2365-2375.
231. Cha S.H., Fukushima A., Sakuma K., Kagawa Y. Chronic docosahexaenoic acid intake enhances expression of the gene for uncoupling protein 3 and affects pleiotropic mRNA levels in skeletal muscle of aged C57BL/6NJcl mice. J Nutr 2001, 131:2636-2642.
232. Murali G., Desouza C.V., Clevenger M.E., Ramalingam R., Saraswathi V. Differential effects of eicosapentaenoic acid and docosahexaenoic acid in promoting the differentiation of 3T3-L1 preadipocytes. Prostaglandins Leukot Essent Fatty Acids 2014, 90:13-21.